Shire PLC (LON:SHP)‘s stock had its “equal weight” rating reaffirmed by research analysts at Barclays PLC in a research report issued to clients and investors on Monday. They presently have a GBX 4,000 ($52.78) price objective on the biopharmaceutical company’s stock. Barclays PLC’s price target suggests a potential upside of 11.13% from the company’s current price.
SHP has been the topic of a number of other reports. Goldman Sachs Group, Inc. (The) reissued a “conviction-buy” rating on shares of Shire PLC in a research note on Tuesday, October 17th. Deutsche Bank AG cut their price target on Shire PLC from GBX 6,000 ($79.18) to GBX 5,700 ($75.22) and set a “buy” rating on the stock in a research note on Tuesday, September 5th. Liberum Capital cut their price target on Shire PLC from GBX 4,900 ($64.66) to GBX 4,400 ($58.06) and set a “hold” rating on the stock in a research note on Friday, August 11th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Shire PLC in a research note on Tuesday, August 22nd. Finally, Morgan Stanley cut their price objective on Shire PLC from GBX 5,800 ($76.54) to GBX 5,700 ($75.22) and set an “overweight” rating on the stock in a research note on Thursday, October 12th. Four analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of GBX 5,640.78 ($74.44).
Shire PLC (SHP) opened at 3656.00 on Monday. The firm’s 50-day moving average is GBX 3,828.99 and its 200-day moving average is GBX 4,188.71. Shire PLC has a 52-week low of GBX 3,435.50 and a 52-week high of GBX 5,186.00. The firm’s market capitalization is GBX 33.14 billion.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2017/10/30/barclays-plc-reiterates-equal-weight-rating-for-shire-plc-shp.html.
In other news, insider Anne Minto acquired 190 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was purchased at an average price of GBX 3,785 ($49.95) per share, for a total transaction of £7,191.50 ($9,489.97). Also, insider Flemming Ornskov acquired 8,400 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average price of GBX 3,665 ($48.36) per share, with a total value of £307,860 ($406,254.95).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.